Open main menu

Psychiatrienet β

Combining-Lithium-Risperidone

Revision as of 19:06, 4 March 2010 by Musys (talk | contribs)
Lithium
Type moodstabilizer
Group other
links
ATC-code N05AN01
Medscape Lithium
PubChem 11125
PubMed Lithium
Drugs.com lithium
Kompas (Dutch) Lithium
Wikipedia Lithium
Risperidone
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AX08
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Drugs.com risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone

Adding risperidone to lithium.

Infobord.png General information
  • Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
  • Risperidone is principally metabolized by CYP2D6 to an active metabolite 9-OH-risperidone (paliperidone).
  • Lithium is eliminated by the kidney for about 95%. Changes in the rate of excretion can cause unwanted effects.
  • Risperidone is principally metabolized by CYP2D6 to an active metabolite.
  • This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
Eenrichtingbord.png Start risperidone
  • Start risperidone according to the general dosing advice.
Letopbord.png Cave
  • The concomitant administration of lithium with neuroleptic agents may increase the risk of extrapyramidal reactions and neurotoxicity.


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.